"People come together, operators, with their supervisors at 6 a.m. every morning, and they talk about what issues they have and how they propose to solve it. Those get escalated through all levels of ...

Novo Nordisk’s semaglutide diabetes and weight loss drugs, Ozempic and Wegovy, are no longer officially in shortage in the US ...

Eli Lilly plans to launch its diabetes and weight-loss drug, Mounjaro, in emerging markets such as India, Brazil, and Mexico in 2025. The expansion leverages growing demand in populous countries ...

Eli Lilly plans to launch Mounjaro, its blockbuster diabetes drug, in countries like China, India, Brazil and Mexico by 2026, ...

Eli Lilly plans to release its diabetes and weight-loss drug, Mounjaro, in major global markets like China, India, Brazil, ...

The federal government has spent $6.2 billion on research and development for weight-loss drugs. Now, thanks to Big Pharma ...

We recently compiled a list of the 30 Best Stocks To Invest In According to Billionaires. In this article, we are going to ...

We recently compiled a list of the Top 10 Stocks to Buy According to Lone Pine Capital. In this article, we are going to take ...

Throughout last year’s entertainment awards season, Lilly took aim at the popular off-label use of GLP-1 drugs like its Mounjaro and Zepbound for cosmetic weight loss. A commercial released ...

The new investments aren't solely dedicated to Eli Lilly's current and future obesity and diabetes treatments. The company is charting its future beyond Zepbound and Mounjaro, with hopes to ...